Rituximab-mediated Raf Kinase Inhibitor Protein Induction Modulates NF-κB in Sjögren Syndrome

Overview

Journal Immunology

Specialty Allergy & Immunology

Date 2014 Mar 25

PMID 24655025

Citations 7

Authors

Margherita Sisto

Sabrina Lisi

Massimo DAmore

Dario D Lofrumento

Affiliations

Soon will be listed here.

Abstract

Primary Sjögren syndrome (pSS) is an autoimmune disorder characterized by an epithelial injury surrounded by dense lymphocytic infiltrates. The conditions for the long-term maintenance of human salivary gland epithelial cells from pSS patients and a co-culture system with pSS lymphocytes were used to assess the effect of Rituximab (RTX) on the inflammatory condition and progression in pSS. Quantitative real-time PCR, genes and protein array analysis, Western blot, flow cytometry, small interfering RNA transfection and nuclear factor-κB (NF-κB) DNA binding assays were used as methods. Supporting the benefits of RTX, this study demonstrates that RTX decreases NF-κB activity and interrupts the NF-κB signalling pathway through the up-regulation of the Raf-1 kinase inhibitor protein (RKIP). Over-expression of RKIP down-regulates interleukins, their receptors and the expression of genes encodes proteins that attracted lymphocytes. Silencing of the RKIP gene leads to significantly increased expression and release of pro-inflammatory mediators supporting that RKIP expression could be involved in the suppression of NF-κB activation in pSS salivary gland epithelial cells.

Citing Articles

RKIP Pleiotropic Activities in Cancer and Inflammatory Diseases: Role in Immunity.

Touboul R, Baritaki S, Zaravinos A, Bonavida B Cancers (Basel). 2021; 13(24).

PMID: 34944867 PMC: 8699197. DOI: 10.3390/cancers13246247.

Understanding the Complexity of Sjögren's Syndrome: Remarkable Progress in Elucidating NF-κB Mechanisms.

Sisto M, Ribatti D, Lisi S J Clin Med. 2020; 9(9).

PMID: 32878252 PMC: 7563658. DOI: 10.3390/jcm9092821.

RKIP as an Inflammatory and Immune System Modulator: Implications in Cancer.

Gabriela-Freitas M, Pinheiro J, Raquel-Cunha A, Cardoso-Carneiro D, Martinho O Biomolecules. 2019; 9(12).

PMID: 31766768 PMC: 6995551. DOI: 10.3390/biom9120769.

The Hajdu Cheney mutation sensitizes mice to the osteolytic actions of tumor necrosis factor α.

Yu J, Canalis E J Biol Chem. 2019; 294(39):14203-14214.

PMID: 31371452 PMC: 6768656. DOI: 10.1074/jbc.RA119.009824.

RKIP: A Key Regulator in Tumor Metastasis Initiation and Resistance to Apoptosis: Therapeutic Targeting and Impact.

Zaravinos A, Bonavida B, Chatzaki E, Baritaki S Cancers (Basel). 2018; 10(9).

PMID: 30149591 PMC: 6162400. DOI: 10.3390/cancers10090287.

References

Mitsias D, Kapsogeorgou E, Moutsopoulos H . The role of epithelial cells in the initiation and perpetuation of autoimmune lesions: lessons from Sjogren's syndrome (autoimmune epithelitis). Lupus. 2006; 15(5):255-61. DOI: 10.1191/0961203306lu2290rr. View

Routsias J, Tzioufas A . Autoimmune response and target autoantigens in Sjogren's syndrome. Eur J Clin Invest. 2010; 40(11):1026-36. DOI: 10.1111/j.1365-2362.2010.02342.x. View

Sisto M, Lisi S, Lofrumento D, DAmore M, Frassanito M, Ribatti D . Sjögren's syndrome pathological neovascularization is regulated by VEGF-A-stimulated TACE-dependent crosstalk between VEGFR2 and NF-κB. Genes Immun. 2012; 13(5):411-20. DOI: 10.1038/gene.2012.9. View

Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P . Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002; 99(3):754-8. DOI: 10.1182/blood.v99.3.754. View

Devauchelle-Pensec V, Pennec Y, Morvan J, Pers J, Daridon C, Jousse-Joulin S . Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum. 2007; 57(2):310-7. DOI: 10.1002/art.22536. View

Gilboa-Geffen A, Wolf Y, Hanin G, Melamed-Book N, Pick M, Bennett E . Activation of the alternative NFκB pathway improves disease symptoms in a model of Sjogren's syndrome. PLoS One. 2011; 6(12):e28727. PMC: 3235165. DOI: 10.1371/journal.pone.0028727. View

Peng B, Ling J, Lee A, Wang Z, Chang Z, Jin W . Defective feedback regulation of NF-kappaB underlies Sjogren's syndrome in mice with mutated kappaB enhancers of the IkappaBalpha promoter. Proc Natl Acad Sci U S A. 2010; 107(34):15193-8. PMC: 2930541. DOI: 10.1073/pnas.1005533107. View

Sens D, Hintz D, Rudisill M, Sens M, SPICER S . Explant culture of human submandibular gland epithelial cells: evidence for ductal origin. Lab Invest. 1985; 52(5):559-67. View

Meijer J, Meiners P, Vissink A, Spijkervet F, Abdulahad W, Kamminga N . Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010; 62(4):960-8. DOI: 10.1002/art.27314. View

10.

Stone J, Merkel P, Spiera R, Seo P, Langford C, Hoffman G . Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010; 363(3):221-32. PMC: 3137658. DOI: 10.1056/NEJMoa0909905. View

11.

Sisto M, DAmore M, Caprio S, Mitolo V, Scagliusi P, Lisi S . Tumor necrosis factor inhibitors block apoptosis of human epithelial cells of the salivary glands. Ann N Y Acad Sci. 2009; 1171:407-14. DOI: 10.1111/j.1749-6632.2009.04688.x. View

12.

Lisi S, Sisto M, Lofrumento D, DAmore M . Sjögren's syndrome autoantibodies provoke changes in gene expression profiles of inflammatory cytokines triggering a pathway involving TACE/NF-κB. Lab Invest. 2011; 92(4):615-24. DOI: 10.1038/labinvest.2011.190. View

13.

Sisto M, Lisi S, Lofrumento D, DAmore M, Scagliusi P, Mitolo V . Autoantibodies from Sjögren's syndrome trigger apoptosis in salivary gland cell line. Ann N Y Acad Sci. 2007; 1108:418-25. DOI: 10.1196/annals.1422.044. View

14.

Sisto M, Lisi S, Lofrumento D, Ingravallo G, Mitolo V, DAmore M . Expression of pro-inflammatory TACE-TNF-α-amphiregulin axis in Sjögren's syndrome salivary glands. Histochem Cell Biol. 2010; 134(4):345-53. DOI: 10.1007/s00418-010-0735-5. View

15.

Hansen A, Lipsky P, Dorner T . Immunopathogenesis of primary Sjögren's syndrome: implications for disease management and therapy. Curr Opin Rheumatol. 2005; 17(5):558-65. DOI: 10.1097/01.bor.0000172801.56744.c3. View

16.

Lisi S, DAmore M, Lofrumento D, Mitolo V, Frassanito M, Dammacco F . Modulation of the Fcgamma receptors induced by anti-Ro and anti-La autoantibodies: observations in salivary gland cells. Rheumatol Int. 2008; 28(9):943-8. DOI: 10.1007/s00296-008-0536-5. View

17.

Pers J, Devauchelle V, Daridon C, Bendaoud B, Le Berre R, Bordron A . BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum. 2007; 56(5):1464-77. DOI: 10.1002/art.22603. View

18.

Youinou P, Pers J . Disturbance of cytokine networks in Sjögren's syndrome. Arthritis Res Ther. 2011; 13(4):227. PMC: 3239335. DOI: 10.1186/ar3348. View

19.

Varin M, Guerrier T, Devauchelle-Pensec V, Jamin C, Youinou P, Pers J . In Sjögren's syndrome, B lymphocytes induce epithelial cells of salivary glands into apoptosis through protein kinase C delta activation. Autoimmun Rev. 2011; 11(4):252-8. DOI: 10.1016/j.autrev.2011.10.005. View

20.

Vitali C, Bootsma H, Bowman S, Dorner T, Gottenberg J, Mariette X . Classification criteria for Sjogren's syndrome: we actually need to definitively resolve the long debate on the issue. Ann Rheum Dis. 2012; 72(4):476-8. DOI: 10.1136/annrheumdis-2012-202565. View